Varda Space Industries
Will Bruey
Data verified as of Jul 29, 2026
Summary
Varda Space Industries manufactures materials in orbit and brings them back to Earth, a business no company had ever run commercially before it. Founded in 2021 by former SpaceX Dragon engineer Will Bruey and Founders Fund partner Delian Asparouhov, it builds the W-Series: free-flying spacecraft that process pharmaceuticals in microgravity and then return the product inside a capsule that reenters at over 18,000 mph and lands under parachute, usually at the Koonibba Test Range in South Australia. The commercial logic is that microgravity produces crystal structures and morphologies that gravity makes impossible on the ground, and Varda proved it on its first flight by growing and recovering the metastable Form III of ritonavir, an HIV antiviral. Six missions have flown since 2023. W-5 returned in January 2026 as the first full mission on Varda's own vertically integrated satellite bus, carrying a U.S. Navy payload, and W-6 returned in May 2026 flying thermal-protection and autonomous-navigation experiments for NASA and defense customers under the AFRL's Prometheus program. That second business, selling the capsule as a cheap, high-cadence hypersonic reentry testbed, now runs alongside the pharmaceutical work. In May 2026 United Therapeutics signed on to develop microgravity formulations for rare pulmonary disease, the first time a publicly traded pharmaceutical company has spent its own capital on commercial drug manufacturing in space.
Main Products
Free-flying orbital production satellite with an integrated reentry capsule. It processes materials in microgravity independently of any space station, then returns the finished product to Earth under parachute.
Six missions launched since 2023 and five capsules recovered. Since W-4 in June 2025 the spacecraft bus has been designed and built entirely in-house at El Segundo rather than bought in, and W-5's January 2026 return was the first complete mission lifecycle flown on Varda hardware end to end.
The W-Series capsule sold as a flight environment rather than a factory: a repeatable, low-cost way for defense and civil customers to test thermal protection materials, sensors, and guidance systems in real hypersonic reentry conditions.
W-6 launched in March 2026 and returned May 19, 2026 as a dedicated testbed flight funded through the Air Force Research Laboratory's Prometheus program, carrying NASA and defense payloads and validating next-generation thermal protection systems and autonomous navigation. W-5 carried a U.S. Navy payload on its January 2026 return.
What's Next
Fly the first United Therapeutics formulation missions
Begin processing small-molecule treatments for rare pulmonary disease aboard W-Series spacecraft under the collaboration announced in May 2026, using microgravity's effect on crystallization to chase formulations with better stability and bioavailability. The partnership covers multiple low Earth orbit missions and is the first time a public pharmaceutical company has funded commercial space manufacturing from its own balance sheet.
Resolve the W-4 capsule's return
Bring back the W-4 demonstration capsule, still on orbit after its December 2025 reentry attempt was called off so Varda could evaluate the propellant feed system. The company said in January 2026 it was weighing a few paths to recovery while prioritizing customer missions.
Operations & Revenue
Varda has flown six W-Series missions since 2023 and recovered five capsules, two of them in 2026 (W-5 in January and W-6 in May), both at Southern Launch's Koonibba Test Range in South Australia. The spacecraft bus is now built entirely in-house at El Segundo, an office is open in Huntsville near NASA Marshall, and the company runs two revenue lines at once: microgravity pharmaceutical processing, anchored by the United Therapeutics partnership signed in May 2026, and a government hypersonic reentry testbed funded through AFRL's Prometheus program. The one outstanding problem is W-4, whose reentry was deferred in December 2025 pending evaluation of its propellant feed system.
Revenue Streams
Pharmaceutical Processing in Microgravity
Contract manufacturing and formulation research for drug companies that want crystal structures and morphologies microgravity makes accessible, sold as processing slots aboard W-Series missions. The United Therapeutics collaboration covers multiple flights for rare pulmonary disease treatments.
Key Metrics
Timeline
Launched November 28, 2025, W-5 lands at Koonibba on January 29, 2026 carrying a U.S. Navy payload. It is the first time Varda has flown a complete mission lifecycle, from orbital operations through reentry, on hardware it designed and built end to end.
In May 2026 Varda and United Therapeutics announce a collaboration to develop microgravity-enabled formulations of small-molecule treatments for rare pulmonary disease across multiple low Earth orbit missions. It is one of the first times a publicly traded pharmaceutical company has invested its own capital in commercial space-based drug manufacturing rather than relying on government-funded research.
Launched in March 2026 and recovered at Koonibba on May 19, 2026, W-6 is optimized for atmospheric flight physics rather than pharmaceutical processing. Funded through the Air Force Research Laboratory's Prometheus program, it carries NASA and defense payloads and validates next-generation thermal protection systems and autonomous navigation during hypersonic reentry.
W-4 launches in June 2025 on SpaceX's Transporter-14 carrying the first spacecraft bus Varda built itself rather than buying from Rocket Lab, and flies under the first reentry vehicle operator license the FAA has ever issued. Its return was deferred in December 2025 while the company evaluated the propellant feed system, and Varda has described W-4 as a demonstration mission with customer flights taking priority.
After months of regulatory delay in obtaining reentry approval, the W-1 capsule lands at the Utah Test and Training Range in February 2024 with its ritonavir sample intact. Varda later publishes results showing it recovered the metastable Form III of the drug, a structure difficult to produce on the ground.
Will Bruey, who worked on Dragon at SpaceX, and Delian Asparouhov, a partner at Founders Fund, found Varda in El Segundo with a single premise: microgravity is a manufacturing environment worth paying for, and the missing piece is a cheap way to bring the product home.
Funding
Cumulative disclosed raise · dated rounds
Related Companies
All Orbital Economy
Astroscale
Orbital Economy +1
Astroscale is the only company in the world building a business purely around servicing what is already in orbit: removing debris, deorbiting dead satellites, extending the life of working ones, refueling them, and inspecting them. Founded in Tokyo in 2013 by Nobu Okada and listed on the Tokyo Stock Exchange Growth market since June 2024 under ticker 186A, it operates across Japan, the UK, the US, France, and Israel. Its ADRAS-J spacecraft made history in 2024 as the first vehicle ever to approach and photograph a large piece of orbital debris up close, a discarded Japanese rocket upper stage, and it completed operations and began its own deorbit in March 2026. JAXA has since contracted the follow-on ADRAS-J2 for roughly 12 billion yen to go back to that same rocket body and actually remove it with a robotic arm. Alongside that flagship line Astroscale is preparing ELSA-M, billed as the world's first commercial end-of-life deorbit service and now booked on Isar Aerospace's Spectrum rocket; LEXI, a geostationary life-extension servicer; the Astroscale U.S. Refueler, which is set to perform the first refueling of a United States Space Force asset; and ISSA-J1, a 2027 mission that will inspect two retired Japanese satellites in different orbits on a single flight. The company remains deeply loss-making: for the fiscal year ended April 30, 2026 it reported 5.94 billion yen of IFRS revenue against a 9.98 billion yen operating loss, with an order backlog of 37.94 billion yen.
Blue Origin
Orbital Economy +1
Blue Origin is a privately held aerospace company founded by Jeff Bezos that develops reusable launch vehicles, rocket engines, lunar landers, in-space mobility systems, and satellite communications infrastructure. Its current programs span the New Shepard suborbital system, the New Glenn heavy-lift rocket, the BE-4 engine family that also powers ULA's Vulcan, the Blue Moon lunar lander family, the Blue Ring spacecraft platform, and the TeraWave network. The FAA closed its NG-3 mishap investigation and lifted the New Glenn grounding on May 22, 2026 - pinning the BlueBird 7 deployment failure on a cryogenic leak that froze a hydraulic line - but six days later, on May 28, a New Glenn exploded during a hotfire at Cape Canaveral's LC-36, destroying the transporter-erector at Blue Origin's only New Glenn pad. CEO Dave Limp said the rocket will fly again before year-end via a hybrid horizontal-integration/crane-erect path that skips replacing the destroyed transporter-erector, with the propellant farm, a second flight-ready booster, and three upper stages intact; on July 24, 2026 NASA and Blue Origin agreed to conduct New Glenn second-stage (GS2) hot fire testing at Stennis Space Center's B-2 stand beginning this fall while LC-36 recovers. The Blue Moon MK1 'Endurance' cargo lunar lander has completed thermal vacuum testing at NASA Johnson, but with New Glenn grounded its launch to the Moon has slipped from a fall-2026 target to early 2027. In a landmark shift after 26 years of near-total self-funding (roughly $30B cumulative), Blue Origin raised about $10B at a $130B valuation in July 2026 - its first-ever outside round, led by Coatue (~$4B) with Jeff Bezos adding ~$2B - to bankroll Limp's target cadence of roughly 100 launches a year against an estimated ~$4.8B 2026 spend.
CASC
Orbital Economy +1
China Aerospace Science and Technology Corporation (CASC) is the state-owned prime contractor for China's space program and the world's most prolific launch organization by missions flown. Wholly owned by the central government through SASAC, it develops and operates the Long March (Changzheng) rocket family - which flew its 650th cumulative mission on June 11, 2026 - along with the Shenzhou crewed spacecraft, Tianzhou cargo vehicles, the Tiangong space station, BeiDou navigation and GuoWang broadband satellites, the Chang'e lunar and Tianwen planetary probes, and China's strategic missiles. After a national-record 73 launches in 2025, CASC is targeting over 100 launches in 2026 amid an industry-wide national push toward ~140, debuted the partially reusable Long March 12B in June 2026, and saw its Tianwen-2 probe reach the quasi-moon asteroid Kamo'oalewa on June 7, 2026. On July 10, 2026 it made China the second nation ever to recover an orbital rocket first stage, when the new single-stick, partially reusable Long March 10B flew its maiden mission from Hainan and captured its booster in a sea-based net - a landmark step toward closing the reusability gap with SpaceX. It is preparing to fly Chang'e 7 to the lunar south pole no earlier than August 2026 while advancing the triple-core Long March 10 toward a crewed Moon landing before 2030.
Firefly Aerospace
Orbital Economy +1
Firefly Aerospace is a public space and defense company that launches the Alpha small-lift rocket, is co-developing the Eclipse medium-lift vehicle with Northrop Grumman, flies Blue Ghost lunar landers, and builds Elytra orbital vehicles for maneuvering, communications, imaging, and other cislunar services. After becoming the first commercial company to complete a fully successful Moon landing, Firefly expanded further into defense software and data systems through its SciTec acquisition, which won a U.S. Space Force Space-Based Interceptor OTA agreement in May 2026 and a $5.5M Air Force CBC2 data-fusion option in June 2026 as part of the Golden Dome architecture. Q1 2026 revenue was $80.9M against $1.3B of backlog, Firefly doubled its Cedar Park campus to 144,000 sq ft to industrialize Blue Ghost and Elytra production, closed a 12M-share follow-on at $48/share on June 1, 2026, and - per June 23, 2026 Reuters reporting - is set to secure a ~$110M EXIM loan to fund further Texas production expansion as it prepares the first full Alpha Block II flight (Flight 8) for late summer 2026. In July 2026 Firefly also won a $13M NASA JPL subcontract - the first out of its new Gloworks innovation lab - to build the aeroshell for NASA's SkyFall Mars helicopter mission, extending it into planetary entry-descent-and-landing hardware.
Impulse Space
Orbital Economy +1
Impulse Space builds the vehicles that move payloads once a rocket has done its job, a business the company calls in-space mobility. It was founded in 2021 by Tom Mueller, SpaceX's founding propulsion engineer and the architect of the Merlin engine, and sells two vehicles: Mira, a highly maneuverable 300 kg-class orbital transfer and hosting spacecraft that has flown three missions since November 2023, and Helios, a high-energy kick stage powered by the 67 kN Deneb methalox engine that is designed to carry a payload from low Earth orbit to geostationary orbit in under a day rather than the months an electric tug needs. In July 2026 the U.S. Space Force awarded Impulse a National Security Space Launch Phase 3 Lane 1 contract, making it the first upper-stage provider ever to hold prime status in a program historically reserved for rocket companies, and in June 2026 the company raised a $500 million Series D that took total funding past $1 billion. Mira has already proven the harder operational trick: in December 2025 two Impulse Mira spacecraft performed a fully autonomous rendezvous in low Earth orbit with Starfish Space's Remora payload aboard. Helios is now targeted for its inaugural flight in 2027, and a third product line, the in-house Electra electric propulsion system, debuts alongside it.
Inversion Space
Orbital Economy +1
Inversion Space, founded in 2021 by Boston University students Justin Fiaschetti and Austin Briggs and backed by Y Combinator, builds reentry vehicles that park cargo in orbit and bring it down on demand, inverting the usual direction of space logistics: instead of launching goods when they are needed, the goods wait overhead and come back within an hour of the request. Its flagship vehicle, Arc, was unveiled on October 1, 2025 as a fully reusable lifting body about four feet across and eight feet tall that stores roughly 500 lb of payload on orbit for up to five years, survives reentry above Mach 20, steers more than 1,000 km of cross-range, and touches down under an autonomously guided parachute within about 50 feet of a target, needing no runway and using non-toxic propellants so crews can approach it immediately. The company has raised roughly $54 million, most of it a $44 million Series A in November 2024 co-led by Spark Capital and Adjacent with Lockheed Martin Ventures and Kindred Ventures, on top of a $71 million STRATFI award from AFRL and SpaceWERX in September 2024. Its pathfinder, the 20-inch Ray capsule, launched on SpaceX's Transporter-12 in January 2025 and validated avionics, power, propulsion, and separation, but a short circuit kept the deorbit engine from igniting, so it never flew the reentry it was built to demonstrate. Defense demand has arrived ahead of the flight record: Inversion was selected into Kratos' $1.45 billion MACH-TB 2.0 hypersonic test program in September 2025 and joined Anduril's team for the Space Force's Golden Dome space-based interceptor work in May 2026. It operates a 55,000-square-foot Los Angeles factory and a five-acre Mojave test site with about 60 employees, and the whole thesis now rests on flying Arc for the first time.